查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086253

醫藥契約製造市場：2026-2032年全球市場預測（依服務類型、分子類型、劑型、合約類型、生產規模及應用分類）

Pharmaceutical Contract Manufacturing Market by Service Type, Molecule Type, Dosage Form, Contract Type, Production Scale, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥品契約製造市場將成長至 2,978.8 億美元，複合年成長率為 10.06%。

主要市場統計數據
基準年 2025 1522.7億美元
預計年份：2026年 1647.1億美元
預測年份 2032 2978.8億美元
複合年成長率 (%) 10.06%

執行摘要：製藥契約製造市場

契約製造已成為生物製藥公司尋求可擴展生產能力、專業技術專長和穩健供應鏈的策略性商業模式。目前，合約研發生產機構（CDMO）支援整個價值鏈，包括原料藥（API）合成、生物製藥生產、無菌填充和包裝、口服固體製劑生產、分析測試、包裝、序列化和商業供應。

醫藥外包環境的變革性變化

該領域的趨勢正從產能驅動外包轉向產能主導夥伴關係。贊助公司優先考慮那些擁有良好合規記錄、能夠提供從研發到商業化的一體化服務、具備高活性原料藥控制專業知識以及擁有靈活生產網路的合約研發生產機構 (CDMO)，這些機構能夠支持加快臨床試驗進度並擴大商業規模。

人工智慧對CDMO營運的累積影響

人工智慧 (AI) 透過改善需求計劃、偏差檢測、流程最佳化、批次記錄審核和預測性維護，正在為 CDMO 營運創造累積價值。根據 FDA 報告顯示，2016 年至 2023 年間，超過 300 項藥品和生技藥品申請提及了人工智慧或機器學習，證實了人工智慧正從實驗階段走向受監管的研發和生產流程。

全球製藥業的關鍵區域洞察

亞太地區仍然是藥品契約製造的關鍵區域。這是因為中國、印度、日本、韓國和澳洲具備原料藥（活性成分）生產能力、生物製藥投資、熟練的科技人才以及日益成熟的監管體系。印度被公認為全球主要的學名藥和疫苗供應商，而中國則在更嚴格的環境和品管條件下，持續提升其生物製藥和原料藥生產能力。

主要組織集團概況：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協，隨著成員國加大對改善醫療保健服務和協調監管的投入，二級加工、包裝和區域分銷的重要性日益凸顯。在海灣合作理事會，藥品在地化進程正在推進，以降低對進口的依賴，這為技術轉移、灌裝包裝以及品牌學名藥的生產創造了機會。

對主要製藥製造市場關鍵國家的洞察

美國仍然是全球最大的創新主導外包市場，這得益於FDA的監管、創業投資支持的生物技術以及對臨床和商業化生產的持續需求。加拿大擁有強大的生技藥品和臨床生產能力，而墨西哥則受益於其接近性美國市場的地理優勢、具有競爭力的生產成本以及對近岸藥品包裝和成品服務日益成長的需求。

為製藥業領導者提供的實用建議

產業領導者應優先考慮雙源策略、檢驗的技術轉移手冊以及貫穿其原料藥、輔料、組分和最終產品網路的透明供應商風險評估。在選擇合約研發生產機構 (CDMO) 時，應考慮綜合因素，不僅要考慮成本，還要考慮法規遵循、審計歷史、產能柔軟性、資料完整性成熟度以及在目標治療領域的經驗。

藥品契約製造分析的調查方法

本執行摘要是基於對公開可檢驗資訊來源的三角驗證，包括監管出版刊物、GMP指南、藥品核准資料庫、企業資訊披露、貿易資料以及已記錄的行業產能趨勢。主要參考資料包括FDA核准統計數據、FDA關於人工智慧和機器學習在藥物研發中的應用討論、ICH品質指南、EMA和歐盟GMP框架以及各國藥品政策趨勢。

結論：醫藥契約製造的策略性展望

醫藥契約製造正步入一個更具策略性的階段，其特徵是複雜性、合規性、數位化和供應鏈韌性。委託企業越來越傾向於尋找能夠在原料藥、生物製藥、無菌製劑和最終產品製劑等各個環節提供技術深度、監管信譽和可擴展執行能力的合約研發生產機構 (CDMO)。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：藥品契約製造市場：依服務類型分類

  • 分析服務
    • 生物分析服務
    • 分析方法的開發
    • 穩定性測試
  • 發展服務
    • 配方開發
    • 製程開發
  • 填充服務
    • 注射器填充
    • 單劑量補充裝
    • 管瓶填充
  • 製造服務
    • 液體
    • 固態口服製劑
    • 無菌注射劑
    • 外用製劑
  • 包裝和標籤
    • 初級包裝
    • 二級包裝

第8章：藥品契約製造市場：依分子類型分類

  • 生物製劑
  • 低分子

第9章：藥品契約製造市場：依劑型分類

  • 液體
    • 口服液
    • 暫停
  • 固態劑型
    • 膠囊
    • 藥片
  • 無菌注射劑
  • 外用製劑
    • 乳膏和軟膏
    • 凝膠

第10章：藥品契約製造市場：依合約類型分類

  • 獨家的
  • 非專用

第11章：醫藥契約製造市場：依生產規模分類

  • 臨床試驗
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業

第12章：醫藥契約製造市場：依應用領域分類

  • 感染疾病
  • 心血管疾病
  • 神經病變
  • 代謝性疾病
  • 自體免疫疾病

第13章：醫藥契約製造市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 藥品契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：藥品契約製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Aenova Group GmbH
  • AGC Biologics
  • Akums Drugs & Pharmaceuticals Ltd.
  • Almac Group
  • Aragen Life Sciences
  • Ardena Holding NV
  • Asymchem Laboratories（Tianjin）Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma
  • Curia Global, Inc.
  • Delpharm
  • Eurofins Scientific SE
  • Evonik Industries AG
  • Fareva SA
  • Fujifilm Diosynth Biotechnologies
  • Jubilant Pharmova Limited
  • Lonza Group Ltd.
  • Merck KGaA
  • Neuland Laboratories Limited
  • PCI Pharma Services
  • Piramal Pharma Solutions
  • Porton Pharma Solutions Ltd.
  • Recipharm AB
  • Sai Life Sciences Ltd.
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • Simtra BioPharma Solutions
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • WuXi AppTec Co., Ltd.
Product Code: MRR-030EE48515DD

The Pharmaceutical Contract Manufacturing Market is projected to grow by USD 297.88 billion at a CAGR of 10.06% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 152.27 billion
Estimated Year [2026] USD 164.71 billion
Forecast Year [2032] USD 297.88 billion
CAGR (%) 10.06%

Executive Summary: Pharmaceutical Contract Manufacturing Market

Pharmaceutical contract manufacturing has become a strategic operating model for biopharmaceutical companies seeking scalable capacity, specialized technical capabilities, and resilient supply. Contract development and manufacturing organizations (CDMOs) now support the full value chain, including active pharmaceutical ingredient (API) synthesis, biologics manufacturing, sterile fill-finish, oral solid dose production, analytical testing, packaging, serialization, and commercial supply.

Demand is supported by verified industry signals: the U.S. FDA Center for Drug Evaluation and Research approved 55 novel drugs in 2023 and 50 in 2024, while biologics, high-potency compounds, cell and gene therapies, and complex injectables continue to require dedicated infrastructure and advanced quality systems. As sponsors balance cost, speed, compliance, and geographic risk, pharmaceutical outsourcing is increasingly viewed as a core component of market access and lifecycle management rather than a tactical capacity decision.

Transformative Shifts in the Pharmaceutical Outsourcing Landscape

The landscape is shifting from capacity-based outsourcing to capability-led partnerships. Sponsors are prioritizing CDMOs with demonstrated compliance records, integrated development-to-commercial services, containment expertise for high-potency APIs, and flexible manufacturing networks that can support accelerated clinical timelines and commercial scale-up.

Regulatory expectations are also reshaping competition. The EU GMP Annex 1 revision strengthened requirements for sterile manufacturing and contamination control, while ICH Q9(R1) reinforced formal quality risk management. These frameworks are raising the value of digital quality systems, validated automation, real-time environmental monitoring, and robust supplier qualification across pharmaceutical contract manufacturing operations.

Cumulative Impact of Artificial Intelligence on CDMO Operations

Artificial intelligence is creating cumulative value across CDMO operations by improving demand planning, deviation detection, process optimization, batch record review, and predictive maintenance. FDA reporting indicates more than 300 drug and biologic submissions referenced AI or machine learning between 2016 and 2023, confirming that AI is moving from experimentation into regulated development and manufacturing workflows.

In contract manufacturing, the strongest near-term impact is expected in quality and operational efficiency rather than full process autonomy. AI-enabled analytics can reduce investigation cycle times, identify recurring root causes, and strengthen continued process verification, but adoption must remain aligned with data integrity, validation, cybersecurity, and human oversight requirements under GMP.

Key Regional Insights Across Global Pharmaceutical Manufacturing

Asia-Pacific remains a pivotal region for pharmaceutical contract manufacturing because China, India, Japan, South Korea, and Australia combine API capacity, biologics investment, skilled scientific labor, and expanding regulatory maturity. India is widely recognized as a major global supplier of generic medicines and vaccines, while China continues to strengthen biologics and API capabilities under tighter environmental and quality controls.

North America is anchored by the United States and Canada, where innovation pipelines, FDA-regulated manufacturing, and demand for sterile injectables, biologics, and advanced therapies sustain premium CDMO services. Latin America, led by Brazil and Mexico, is gaining attention for regional supply resilience and access to large public health systems, although regulatory harmonization and technology transfer readiness remain important differentiators.

Europe benefits from mature GMP infrastructure, strong pharmaceutical clusters in Germany, France, Italy, Spain, and the United Kingdom, and demand for specialized manufacturing under EMA and national authority oversight. The Middle East is investing in localization, with GCC countries prioritizing pharmaceutical security and technology transfer, while Africa's opportunities are linked to essential medicines, vaccine capacity, and long-term public-private manufacturing initiatives focused on improved regional access.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN is becoming more relevant for secondary manufacturing, packaging, and regional distribution as member economies invest in healthcare access and regulatory alignment. The GCC is pursuing pharmaceutical localization to reduce import dependence, creating opportunities for technology transfer, fill-finish, and branded generic production.

The European Union remains one of the most highly regulated and strategically important pharmaceutical manufacturing blocs, supported by harmonized GMP standards and cross-border supply chains. BRICS countries collectively influence global API supply, generics manufacturing, and healthcare demand, with China and India holding particularly significant positions in pharmaceutical inputs and finished-dose production.

G7 markets remain central to high-value outsourcing because they concentrate innovative drug development, advanced regulatory expectations, and sophisticated quality requirements. NATO economies are also reassessing medical supply chain resilience, making domestic and allied-nation manufacturing capacity more strategically important for essential medicines, injectables, vaccines, and critical healthcare products.

Key Country Insights Across Leading Pharmaceutical Manufacturing Markets

The United States remains the largest innovation-driven outsourcing environment, supported by FDA oversight, venture-backed biotechnology, and sustained demand for clinical and commercial manufacturing. Canada offers strong biologics and clinical manufacturing capabilities, while Mexico benefits from proximity to the U.S. market, competitive production economics, and growing interest in nearshore pharmaceutical packaging and finished-dose services.

Brazil is Latin America's largest pharmaceutical market and supports opportunities in generics, biosimilars, and public health supply. The United Kingdom maintains strength in life sciences research and advanced therapy development, while Germany, France, Italy, and Spain provide established GMP manufacturing ecosystems, skilled labor, and strong links to European supply chains. Russia retains domestic production priorities, particularly for essential medicines and import substitution.

China continues to scale API, biologics, and integrated CDMO services, while India remains a global leader in generics, APIs, and vaccine manufacturing. Japan emphasizes high-quality manufacturing and regulatory precision, Australia supports clinical trial supply and specialized biomanufacturing, and South Korea has become a recognized center for large-scale biologics and biosimilar production.

Actionable Recommendations for Pharmaceutical Industry Leaders

Industry leaders should prioritize dual-source strategies, validated technology transfer playbooks, and transparent supplier risk scoring across API, excipient, component, and finished-dose networks. CDMO selection should weigh regulatory history, audit performance, capacity flexibility, data integrity maturity, and experience with the target modality rather than cost alone.

Executives should also invest in digital quality management, AI-ready data architecture, and advanced analytics for batch release, deviation management, and process monitoring. For sponsors, the strongest partnerships will be built around shared governance, clear escalation pathways, lifecycle cost visibility, and jointly defined metrics for quality, speed, yield, and supply continuity.

Research Methodology for the Pharmaceutical Contract Manufacturing Analysis

This executive summary is based on triangulation of publicly available and verifiable sources, including regulatory agency publications, GMP guidance, drug approval databases, company disclosures, trade data, and documented industry capacity trends. Key references include FDA approval statistics, FDA discussions on AI and machine learning in drug development, ICH quality guidelines, EMA and EU GMP frameworks, and national pharmaceutical policy signals.

The analysis emphasizes evidence-backed market drivers, regulatory developments, regional manufacturing capabilities, and observable outsourcing patterns. Qualitative insights were assessed through cross-comparison of sponsor needs, CDMO service models, supply chain resilience priorities, and technology adoption in regulated pharmaceutical manufacturing.

Conclusion: Strategic Outlook for Pharmaceutical Contract Manufacturing

Pharmaceutical contract manufacturing is entering a more strategic phase defined by complexity, compliance, digitalization, and supply chain resilience. Sponsors increasingly require CDMOs that can deliver technical depth, regulatory confidence, and scalable execution across APIs, biologics, sterile products, and finished dosage forms.

As AI, advanced analytics, and global supply diversification mature, competitive advantage will shift toward organizations that combine operational excellence with validated digital systems and regionally resilient networks. Organizations that align outsourcing strategy with quality, risk, and speed-to-market objectives will be best positioned to capture long-term value in the pharmaceutical contract manufacturing market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical Contract Manufacturing Market, by Service Type

  • 7.1. Analytical Services
    • 7.1.1. Bioanalytical Services
    • 7.1.2. Method Development
    • 7.1.3. Stability Studies
  • 7.2. Development Services
    • 7.2.1. Formulation Development
    • 7.2.2. Process Development
  • 7.3. Filling Services
    • 7.3.1. Syringe Filling
    • 7.3.2. Unit Dose Filling
    • 7.3.3. Vial Filling
  • 7.4. Manufacturing Services
    • 7.4.1. Liquid Orals
    • 7.4.2. Solid Oral Dosage
    • 7.4.3. Sterile Injectables
    • 7.4.4. Topical Formulations
  • 7.5. Packaging & Labeling
    • 7.5.1. Primary Packaging
    • 7.5.2. Secondary Packaging

8. Pharmaceutical Contract Manufacturing Market, by Molecule Type

  • 8.1. Biologics
  • 8.2. Small Molecule

9. Pharmaceutical Contract Manufacturing Market, by Dosage Form

  • 9.1. Liquid Dosage
    • 9.1.1. Oral Solutions
    • 9.1.2. Suspensions
  • 9.2. Solid Dosage
    • 9.2.1. Capsules
    • 9.2.2. Tablets
  • 9.3. Sterile Injectables
  • 9.4. Topical Dosage
    • 9.4.1. Creams & Ointments
    • 9.4.2. Gels

10. Pharmaceutical Contract Manufacturing Market, by Contract Type

  • 10.1. Dedicated
  • 10.2. Non Dedicated

11. Pharmaceutical Contract Manufacturing Market, by Production Scale

  • 11.1. Clinical Trial
    • 11.1.1. Phase I
    • 11.1.2. Phase II
    • 11.1.3. Phase III
  • 11.2. Commercial

12. Pharmaceutical Contract Manufacturing Market, by Application

  • 12.1. Infectious Diseases
  • 12.2. Cardiovascular Diseases
  • 12.3. Neurological Disorders
  • 12.4. Metabolic Disorders
  • 12.5. Autoimmune Diseases

13. Pharmaceutical Contract Manufacturing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Pharmaceutical Contract Manufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pharmaceutical Contract Manufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Aenova Group GmbH
  • 17.2. AGC Biologics
  • 17.3. Akums Drugs & Pharmaceuticals Ltd.
  • 17.4. Almac Group
  • 17.5. Aragen Life Sciences
  • 17.6. Ardena Holding NV
  • 17.7. Asymchem Laboratories (Tianjin) Co., Ltd.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Cambrex Corporation
  • 17.10. Catalent, Inc.
  • 17.11. Charles River Laboratories International, Inc.
  • 17.12. CordenPharma
  • 17.13. Curia Global, Inc.
  • 17.14. Delpharm
  • 17.15. Eurofins Scientific SE
  • 17.16. Evonik Industries AG
  • 17.17. Fareva SA
  • 17.18. Fujifilm Diosynth Biotechnologies
  • 17.19. Jubilant Pharmova Limited
  • 17.20. Lonza Group Ltd.
  • 17.21. Merck KGaA
  • 17.22. Neuland Laboratories Limited
  • 17.23. PCI Pharma Services
  • 17.24. Piramal Pharma Solutions
  • 17.25. Porton Pharma Solutions Ltd.
  • 17.26. Recipharm AB
  • 17.27. Sai Life Sciences Ltd.
  • 17.28. Samsung Biologics Co., Ltd.
  • 17.29. Siegfried Holding AG
  • 17.30. Simtra BioPharma Solutions
  • 17.31. Syngene International Limited
  • 17.32. Thermo Fisher Scientific Inc.
  • 17.33. Vetter Pharma-Fertigung GmbH & Co. KG
  • 17.34. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOANALYTICAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOANALYTICAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOANALYTICAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METHOD DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METHOD DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METHOD DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STABILITY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STABILITY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STABILITY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FILLING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FILLING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FILLING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYRINGE FILLING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYRINGE FILLING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYRINGE FILLING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UNIT DOSE FILLING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UNIT DOSE FILLING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UNIT DOSE FILLING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIAL FILLING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VIAL FILLING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIAL FILLING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID ORALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID ORALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIQUID ORALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLID ORAL DOSAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOLID ORAL DOSAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOLID ORAL DOSAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STERILE INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STERILE INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STERILE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOPICAL FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOPICAL FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TOPICAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PACKAGING & LABELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PACKAGING & LABELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PACKAGING & LABELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRIMARY PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRIMARY PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRIMARY PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SECONDARY PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SECONDARY PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SECONDARY PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIQUID DOSAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIQUID DOSAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIQUID DOSAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SOLID DOSAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SOLID DOSAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SOLID DOSAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL STERILE INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL STERILE INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL STERILE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TOPICAL DOSAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TOPICAL DOSAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TOPICAL DOSAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CREAMS & OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CREAMS & OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CREAMS & OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DEDICATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DEDICATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DEDICATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NON DEDICATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON DEDICATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NON DEDICATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CLINICAL TRIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CLINICAL TRIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CLINICAL TRIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 260. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 266. GCC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 302. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 305. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 306. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 308. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 309. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 310. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, 2018-2032 (USD MILLION)
  • TABLE 314. G7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 318. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 319. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY FILLING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 320. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 321. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING & LABELING, 2018-2032 (USD MILLION)
  • TABLE 322. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 324. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE, BY SOLID DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 326. NATO P